Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects

Tsuyama, Naoko; Sakamoto, Kana; Sakata, Seiji; Dobashi, Akito; Takeuchi, Kengo

doi:10.3960/jslrt.17023

Cited by 83 publications

(100 citation statements)

References 214 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, prognostic factors include age, serum LDH level, β 2 microglobulin level, time of relapse or progression after the first treatment, extranodular involvement, histological type, etc. Naoko Tsuyama et al [46] concluded previous study stating that the prognosis of ALK-ALCL and ALK+ ALCL before age 40 is not significantly different. After 40 years of age, the prognosis of ALK-ALCL is worse than that of ALK + ALCL.…”

Section: Prognosismentioning

confidence: 95%

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Wang

Zhang

2019

Hematology

View full text Add to dashboard Cite

Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (ALK-ALCL) is a definite entity in the WHO 2016 Classification that represents 2-3% of non-Hodgkin lymphoma (NHL) and 12% of T-cell NHL cases. ALK-ALCL lacks ALK protein expression, but expresses CD30 and has morphologic features similar to ALK positive anaplastic large cell lymphoma (ALK+ ALCL). Some studies indicate that ALK-ALCL and ALK+ ALCL possess different molecular and genetic characteristics. Besides, ALK-ALCL is worse than ALK+ ALCL in terms of treatment outcome, prognosis, and long-term survival. This review is aimed at summarizing information about ALK-ALCL, especially with respect to the treatment and prognosis.

show abstract

Section: Prognosismentioning

confidence: 95%

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Wang

Zhang

2019

Hematology

View full text Add to dashboard Cite

show abstract

“…Yet, for patients younger than 60 years an age adjusted IPI based on three prognostic factors (stage, performance status and LDH level) has been developed. 5…”

Section: Introductionmentioning

confidence: 99%

Comparison of the efficacy of 3-weekly chop with CHOEP for treatment of patients with aggressive non-Hodgkin’s lymphoma.

Mehmood

Khalid

Mehmood

et al. 2020

TPMJ

View full text Add to dashboard Cite

Objectives: To compare the efficacy of 3-weekly CHOP with CHOEP for the treatment of patients with aggressive Non-Hodgkin’s Lymphoma. Study Design: Randomized control trial. Setting: Department of Medical Oncology, Jinnah Hospital Lahore. Period: From January 2016 to June 2016. Material & Methods: Conducted on 200 patients of biopsy confirmed aggressive non-Hodgkin’s lymphoma. The cases were allocated into two groups by using random numbers table i.e. group A & B having 100 patients each. Group A received CHOP-21 regimen which is defined as cyclophosphamide (750mg/m2 intravenously), doxorubicin (50mg/m2 intravenously), vincristine (2mg i/v) & prednisone (100mg/m2 d1-5 PO). Group B received CHOEP-21 regimen which is defined same as CHOP-21 but with the addition of etoposide 100mg/m2 intravenously for day 1-3. Observation regarding efficacy was including all the number of cases in which complete remission of disease was noted one month after completion of chemotherapy. Results: The mean age of the patients in group A was 44.6±13.9 years and in group B was 45.6±11.5 years. In group A, 74 (74%) male and 26 (26%) female patients and in group B, 72 (72%) male and 28 (28%) female patients. In the distribution of patients by complete response after 6 cycles, in group A, 66 (66%) patients had complete response, 30 (30%) patients had partial response, 1 (1%) patient expired, 2 (2%) patients had progressive disease (shifted to salvage therapy) and 1 (1%) patient lost the follow up. In group B, 80 (80%) patients had complete response, 16 (16%) patients had partial response, 2 (2%) patients expired, and 2 (2%) patients lost the follow up. Conclusion: It is concluded from this study that viability was accomplished in a greater number of patients treated with CHOEP-21 than those treated with CHOP-21 in the management of patients with aggressive Non hodgkin's lymphoma.

show abstract

“…Anaplastic large cell lymphoma (ALCL) is a rare hematological neoplasia representing only two percent of all non-Hodgkin’s lymphomas ( 1 ). Approximately 50% percent of patients with ALCLs bear a translocation of chromosome two and five t(2;5) fusing the N-terminal part of the protein nucleophosmin (NPM) to the kinase domain of anaplastic lymphoma kinase (ALK), which results in permanent tyrosine kinase activity ( 1 ). ALK-positivity is not unique to ALCL but can be found in various other tumor entities, e.g., in subgroups of non-small cell lung cancer (NSCLC) ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report

et al. 2020

View full text Add to dashboard Cite

Anaplastic large cell lymphoma (ALCL) with ALK-translocation constitutes an aggressive lymphoma with high sensitivity to anthracycline-based chemotherapy. Relapse, however, is observed in about one-third of patients. Salvage treatment incorporates high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation, treatment with the CD30-specific immunoconjugate Brentuximab vedotin (BV) and the use of ALK-inhibitors, such as crizotinib. In this case report, we present a patient with a rare late relapse of ALK-positive ALCL following chemotherapy, who was neither eligible for high-dose chemotherapy nor treatment with BV. Relapse therapy was carried out with daily crizotinib, which rapidly mediated complete regression of all ALCL manifestations. In light of few clinical trials published on the use of crizotinib against ALCL, we want to further substantiate the efficacy of crizotinib as salvage therapy in patients with relapsed ALCL especially if ineligible for high-dose chemotherapy or BV treatment. Finally, we would like to enhance vigilance for potential late relapse of ALCL more than a decade after frontline treatment.

show abstract

Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects

Cited by 83 publications

References 214 publications

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Comparison of the efficacy of 3-weekly chop with CHOEP for treatment of patients with aggressive non-Hodgkin’s lymphoma.

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report

Contact Info

Product

Resources

About